Close
Novotech
Jabsco PureFlo 21 Single Use

Australian Cell Graft For Nervous System Gets Funding Boost

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

How Mobile Field Hospitals Are Changing Emergency Care

Healthcare systems can collapse overnight, particularly in natural disasters...

How Automation Is Transforming Mail-Order Pharmacy Operations: Efficiency, Accuracy and ROI

This article includes: Expanding the Role of Mail-Order Pharmacies ...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.
- Advertisement -

Griffith University, based in Australia, has gone on to conduct a world-first study when it comes to cell transplantation so as to repair nervous system injuries and has thus received a tremendous boost of a $5.4 million fund extension from the Motor Accident Insurance Commission.

Professor James St. John, who happens to head the Griffith’s Clem Jones Centre for Neurobiology and Stem Cell Research, has confirmed that they are coming up with cell transplantation therapies in order to treat injuries that are related to the nervous system.

The research team, under the guidance of Professor John, has gone on to develop a world-first cellular nerve bridge, which has already received a couple of major national awards, namely the NHMRC Marshall and Warren Innovation Award for 2019 and the Research Australia Discovery Award for 2020–21.

The latest round of funding is going to allow the research team at Griffith to expand the horizons of the nerve build technology to a range of nervous system injuries that happen to be wider, including brain as well as peripheral nerve injuries.

It is well to be noted that the new MAIC funding, which will be worth $5.4 million, will add up to a total investment from MAIC to the tune of $16 million since 2017, with the prime focus being on the development of a therapy related to spinal cord injury.

Latest stories

Related stories

How Mobile Field Hospitals Are Changing Emergency Care

Healthcare systems can collapse overnight, particularly in natural disasters...

How Automation Is Transforming Mail-Order Pharmacy Operations: Efficiency, Accuracy and ROI

This article includes: Expanding the Role of Mail-Order Pharmacies ...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »